BioCardia reports FY2022 net loss $11.9M, cash runway into Q3 2023; clinical milestones ahead

BioCardia, Inc.

Net loss $11.9M in 2022 vs $12.6M in 2021; revenue $1.4M up from $1.0M.
Cash $7.4M at year-end provides runway into Q3 2023.
CardiAMP Phase III heart failure trial enrolled 119 patients; DSMB cleared, adaptive SAP submitted.
NK1R+ MSC allogeneic trial for HFrEF (BCDA-03) IND approved; first patient expected Q2 2023.
Japan submission for CardiAMP approval planned for Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BioCardia, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

BioCardia, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-008313

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.